Eight new meds backed for approval by EMA's CHMP

At its March 23-26 meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended eight medicines for approval at its March 2020 meeting. In line with EMA’s measures to limit the spread of COVID-19, the meeting was held virtually.

The European Commission will review the CHMP recommendation and a final decision on the Marketing Authorization Applications is expected in the coming months.

The Committee recommended granting a conditional marketing authorization for Swiss pharma giant Novartis’ (NOVN: VX) Zolgensma (onasemnogene abeparvovec), an advanced therapy medicinal product (ATMP) for the treatment of babies and young children with spinal muscular atrophy, a rare and often fatal genetic disease that causes muscle weakness and progressive loss of movement.